Tarsus Pharmaceuticals

OverviewSuggest Edit

Tarsus Pharmaceuticals is a biopharmaceutical company focused on the development of therapeutic candidates to address large market opportunities initially in ophthalmic conditions. Its lead product candidate, TP-03, is a therapeutic in Phase 2b/3 that is developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis.

TypePublic
Founded2017
HQIrvine, CA, US
Websitetarsusrx.com

Latest Updates

Employees (est.) (Jun 2020)12
Share Price (Nov 2021)$27.2(-1%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Tarsus Pharmaceuticals

Michael Ackermann

Michael Ackermann

Co-founder and Chairman
Bobak Azamian

Bobak Azamian

Co-founder, President, and Chief Executive Officer, Director
Leo Greenstein

Leo Greenstein

Chief Financial Officer
Sesha Neervannan

Sesha Neervannan

Chief Operating Officer
Bryan Wahl

Bryan Wahl

General Counsel
Aziz Mottiwala

Aziz Mottiwala

Chief Commercial Officer
Show more

Tarsus Pharmaceuticals Office Locations

Tarsus Pharmaceuticals has an office in Irvine
Irvine, CA, US (HQ)
15440 Laguna Canyon Rd #160
Irvine, CA, US
19782 MacArthur Blvd #285
Show all (2)

Tarsus Pharmaceuticals Financials and Metrics

Tarsus Pharmaceuticals Revenue

USD

Revenue (Q1, 2021)

33.4m

Net income (Q1, 2021)

10.4m

EBIT (Q1, 2021)

10.7m

Market capitalization (12-Nov-2021)

568.4m

Closing stock price (12-Nov-2021)

27.2

Cash (31-Mar-2021)

156.2m

EV

412.9m
Tarsus Pharmaceuticals's current market capitalization is $568.4 m.
Annual
USDFY, 2018FY, 2019FY, 2020

General and administrative expense

449.0k1.1m8.2m

R&D expense

901.0k3.2m18.8m

Operating expense total

1.4m4.3m27.0m

EBIT

(1.3m)(4.3m)(27.0m)
Half Year
USDH1, 2019H1, 2020

General and administrative expense

514.0k2.1m

R&D expense

2.1m3.2m

Operating expense total

2.6m5.4m

EBIT

(2.6m)(5.4m)
Quarterly
USDQ3, 2020Q1, 2021

Revenue

33.4m

General and administrative expense

2.2m5.2m

R&D expense

8.0m16.3m

Operating expense total

10.1m21.4m
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

2.4m58.0m168.1m

Accounts Receivable

20.0k

Prepaid Expenses

2.5m

Current Assets

2.4m58.0m170.7m
Quarterly
USDQ2, 2020Q3, 2020Q1, 2021

Cash

53.1m86.3m156.2m

Accounts Receivable

1.0k25.0m

Prepaid Expenses

2.7m2.8m

Current Assets

54.7m89.1m191.5m
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(1.3m)(4.7m)(26.8m)

Depreciation and Amortization

1.0k37.0k96.0k

Accounts Payable

131.0k245.0k3.2m

Cash From Operating Activities

(1.2m)(3.7m)(21.1m)
Quarterly
USDQ2, 2019Q2, 2020Q3, 2020Q1, 2021

Net Income

(2.6m)(5.2m)(15.3m)10.4m

Depreciation and Amortization

9.0k32.0k56.0k64.0k

Accounts Payable

261.0k2.0m3.0m5.1m

Cash From Operating Activities

(2.3m)(4.6m)(11.1m)(11.8m)
USDFY, 2018

Financial Leverage

-1.8 x
Show all financial metrics

Tarsus Pharmaceuticals Operating Metrics

Q2, 2020

Pre-Clinical Phase Products

4

Phase III Trials Products

1
Show all operating metrics

Tarsus Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Tarsus Pharmaceuticals Online and Social Media Presence

Embed Graph

Tarsus Pharmaceuticals News and Updates

Tarsus Pharmaceuticals, Inc. Presents Data from Two Pioneering Studies on the Prevalence and Impact of Demodex Blepharitis at the American Academy of Optometry 2021 Annual Meeting

Titan real-world prevalence study data reveals that Demodex blepharitis accounts for over two-thirds of all blepharitis cases and is highly prevalent in many commonly seen patient groups

Tarsus Pharmaceuticals, Inc. Reports Second Quarter 2021 Financial Results and Provides Business and Clinical Updates

Announced positive results of the Saturn-1 pivotal trial evaluating TP-03 for the treatment of Demodex blepharitis; results presented at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) conference

Tarsus Pharmaceuticals, Inc. to Participate in the Raymond James 2021 Human Health Innovation Conference

IRVINE, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today…

Tarsus Pharmaceuticals, Inc. Announces Positive Results of Saturn-1 Pivotal Trial Evaluating TP-03 for the Treatment of Demodex Blepharitis

Saturn-1 Phase 2b/3 trial met all primary and secondary endpoints, and demonstrated significant, clinically meaningful outcomes with no serious treatment-related adverse events and no treatment-related discontinuations, demonstrating the potential of TP-03 to treat Demodex blepharitis, a disease wit…

Tarsus Pharmaceuticals, Inc. Schedules Conference Call and Webcast to Announce Saturn-1 Phase 2b/3 Pivotal Trial Results for TP-03 for the Treatment of Demodex Blepharitis

IRVINE, Calif., June 18, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today…

Tarsus Pharmaceuticals, Inc. Initiates Phase 1 Callisto Trial of TP-05, a Novel, Oral, Non-Vaccine Therapeutic for the Prevention of Lyme Disease

More than 30 million Americans at risk for Lyme disease exposure, which can result in severe neurological and other debilitating symptoms
Show more

Tarsus Pharmaceuticals Frequently Asked Questions

  • When was Tarsus Pharmaceuticals founded?

    Tarsus Pharmaceuticals was founded in 2017.

  • Who are Tarsus Pharmaceuticals key executives?

    Tarsus Pharmaceuticals's key executives are Michael Ackermann, Bobak Azamian and Leo Greenstein.

  • How many employees does Tarsus Pharmaceuticals have?

    Tarsus Pharmaceuticals has 12 employees.

  • Who are Tarsus Pharmaceuticals competitors?

    Competitors of Tarsus Pharmaceuticals include Egis Pharmaceuticals, China Biologic Products and Sunovion Pharmaceuticals.

  • Where is Tarsus Pharmaceuticals headquarters?

    Tarsus Pharmaceuticals headquarters is located at 15440 Laguna Canyon Rd #160, Irvine.

  • Where are Tarsus Pharmaceuticals offices?

    Tarsus Pharmaceuticals has an office in Irvine.

  • How many offices does Tarsus Pharmaceuticals have?

    Tarsus Pharmaceuticals has 2 offices.